Condition
Myoepithelial Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Unknown2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06239272Phase 1Recruiting
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT03874455Unknown
Tazemetostat Expanded Access Program for Adults With Solid Tumors
NCT01586767Not ApplicableUnknown
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
Showing all 3 trials